Elevated mitochondrial O-GlcNAcylation caused by hyperglycemia, as occurs in diabetes, significantly contributes to mitochondrial dysfunction and to diabetic cardiomyopathy. However, little is known about the enzymology of mitochondrial O-GlcNAcylation. Herein, we investigated the enzymes responsible for cycling O-GlcNAc on mitochondrial proteins and studied the mitochondrial transport of UDP-GlcNAc. Analyses of purified rat heart mitochondria from normal and streptozocin-treated diabetic rats show increased mitochondrial O-GlcNAc transferase (OGT) and a concomitant decrease in the mito-specific O-GlcNAcase (OGA). Strikingly, OGT is mislocalized in cardiac mitochondria from diabetic rats. Interaction of OGT and complex IV observed in normal rat heart mitochondria is visibly reduced in diabetic samples, where OGT is mislocalized to the matrix. Live cell OGA activity assays establish the presence of O-GlcNAcase within the mitochondria. Furthermore, we establish that the inner mitochondrial membrane transporter, pyrimidine nucleotide carrier, transports UDP-GlcNAc from the cytosol to the inside of the mitochondria. Knockdown of this transporter substantially lowers mitochondrial O-GlcNAcylation. Inhibition of OGT or OGA activity within neonatal rat cardiomyocytes significantly affects energy production, mitochondrial membrane potential, and mitochondrial oxygen consumption. These data suggest that cardiac mitochondria not only have robust O-GlcNAc cycling, but also that dysregulation of O-GlcNAcylation likely plays a key role in mitochondrial dysfunction associated with diabetes.
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diabetes | diabetic cardiomyopathy | mitochondria | O-GlcNAc | O-GlcNAc transferase P rotein O-GlcNAcylation is a nutrient sensor occurring within nuclear, cytoplasmic, and mitochondrial cellular compartments (1) (2) (3) . Using UDP-GlcNAc, O-GlcNAc transferase (OGT) modifies myriad proteins on serine and/or threonine residues (4) . Cycling of O-GlcNAc is also maintained by an O-GlcNAcase (OGA) (5, 6) . O-GlcNAcylation regulates protein functions in response to nutrient availability, metabolic state, and cellular stress levels (7, 8) . The extent of protein O-GlcNAcylation at a site on a protein is determined collectively by the cycling enzyme activities, specificities, localizations, and by the concentration of UDP-GlcNAc. Thus, an understanding of protein O-GlcNAcylation's biological roles must take into account the presence, expression, interactions, and levels of these important players in the O-GlcNAc cycle.
Increased protein O-GlcNAcylation within chronic high glucose-mediated diabetic tissues indicates a causal link between high O-GlcNAcylation and diabetes (9) . Within the cardiovascular system, significant levels of O-GlcNAcylation have been observed on myofilament proteins, which severely affect contractile force generation (10) . Alterations in cardiac O-GlcNAc levels significantly affect Ca 2+ handling and Serca2a function (11) . STIM1 a modulator of cardiomyocyte calcium entry is modified by O-GlcNAc, which affects cellular calcium translocation (12) . Modification of CaMKII by O-GlcNAc during diabetes activates it to sensitize Ca 2+ release from the sarcoplasmic reticulum causing cardiac mechanical dysfunction and arrhythmias (13, 14) . Both ADP and Ca 2+ signals control ATP production by the mitochondria. Mitochondria are also significantly regulated by nutrient levels and by calcium trafficking in the cell.
Because O-GlcNAc is an end point of nutrient-sensitive pathways, and O-GlcNAcylation significantly affects calcium handling, it stands to reason that this Post translational modification (PTM) exerts influence on mitochondrial function. Indeed, PGC1α, the master regulator of mitochondrial biogenesis and survival is O-GlcNAc modified and serves as a cofactor targeting OGT to FOXO transcription factors (15, 16) . O-GlcNAcylation of Milton affects mitochondrial motility in neurons (17) . Hu et al. reported the modification of mitochondrial electron chain complexes by O-GlcNAc, which affected activities of complexes I, II, and IV (18) . Altering O-GlcNAc levels by overexpression of cytoplasmic OGT or OGA had significant effects on mitochondrial function and mitochondrion-related protein expression (19) . The existence of a mitochondrial isoform of OGT suggests that O-GlcNAcylation occurs within the mitochondria and on mito-specific proteins (20, 21) . However, there have been no reports of an O-GlcNAc hydrolase activity within the mitochondria, as well as no reported mechanism of donor nucleotide sugar (UDP-GlcNAc) presence or import inside the mitochondria (22) .
In this paper, we find that not only are the levels of mitochondrial OGT and OGA dramatically altered in mitochondria from diabetic hearts, but we also show that OGT is mislocalized in diabetic mitochondria. We use live cell imaging to show the presence of OGA within the mitochondria and report the presence of a specific mitochondrial transporter that imports UDP-GlcNAc. Together our data suggest that not only does O-GlcNAcylation appear to regulate mitochondrial functions in normal cells, but also that diabetesassociated changes in O-GlcNAcylation likely contribute to mitochondrial dysfunction associated with diabetic cardiomyopathy.
Significance
Mitochondrial dysfunction contributes significantly to glucose toxicity in diabetes. Increased O-GlcNAcylation is emerging as a major molecular cause of glucose toxicity via many mechanisms. The studies herein provide a direct molecular link between hyperglycemia and mitochondrial dysfunction. We show that mitochondrial O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA) expression levels and localizations are strikingly different between normal and diabetic rat hearts. We also discover how UDP-GlcNAc enters the mitochondrial space. Finally our data demonstrate that OGT and OGA play significant roles in ATP production, mitochondrial membrane potential, and oxygen consumption. These studies are of general interest not only with respect to nutrient regulation of mitochondrial function, but also are important to elucidate mechanisms of diabetic complications.
Results

Mitochondrial OGT Is Increased and Mislocalized in Diabetic Rat
Hearts. Mitochondria purified (Fig. S1 ) from normal and streptozocin (STZ)-treated rat hearts were analyzed by Transmission Electron Microscopy (TEM) for levels of overall protein O-GlcNAc. Using an anti-O-GlcNAc antibody (RL2), we observed significant increases in the total O-GlcNAc levels in the STZ-treated rat mitochondria compared with control rats (Fig. 1A) . Quantifying gold particles indicated more than twofold increases in mitochondrial protein O-GlcNAcylation in diabetic heart samples (Fig. 1B) . Western blot analysis of purified mitochondrial lysates also showed a twofold increase in the levels of mitochondrial OGT (observed around 105 kDa) in diabetic samples ( Fig. 1 C and D) . Western blots showed a band at 78 kDa, indicating that the short isoform of OGT is also present in the mitochondria (Fig. 1C) . TEM analysis on mito sections validates the twofold increase in OGT levels as observed by immunoblotting ( Fig. 1 E and F) . Closer examination of OGT-labeled mitochondria revealed a distinct difference in the localization of gold particles between normal and diabetic samples. Localization of total mitochondrial OGT for control rats was mostly on the inner membrane of the purified mitochondria. In contrast, for diabetic rats, there is a significant amount of matrix localization of OGT (Fig. 1 E and G) . The overall in vitro activity of mitochondrial OGT from purified mitochondrial lysate was observed to be similar for the normal and diabetic samples ( Fig. 1E) (23) . Thus, more OGT protein is required to maintain activity levels similar to normal, indicating a potential reduction in specific activity of mito-specific OGT in diabetic samples.
Interaction of OGT with Mitochondrial Electron Transport Chain
Complex IV in Normal Rats Is Greatly Reduced in Diabetic Animals.
To examine the associations of mitochondrial OGT, we analyzed the mitochondrial samples using Blue Native PAGE. With an anti-OGT antibody, we observed a band at 78 kDa for both normal and diabetic samples ( Fig. 2A) . Whereas the normal samples showed a high association of OGT with complex IV proteins, in the diabetic samples more OGT is associated with complex III (Fig. 2A) . To confirm this observation, we performed immunoprecipitation (IP) experiments of these complexes and immunoblotting for OGT. For complex IV immunoprecipitations, we observed a similar band at 78 kDa for the normal samples, which was reduced in the diabetic samples (Fig. 2 B and C) . The O-GlcNAcylation pattern of complex IV subunits in the immunoprecipitated samples show changes in O-GlcNAc levels in a number of bands (Fig. 2D) . We also observed a reduction in complex IV activity within diabetic rat heart mitochondria (Fig. 2 F and G) . It has previously been reported that high-glucose-treated cardiomyocytes show significant loss in complex IV activity (11, 18) . Our results directly implicate O-GlcNAcylation in the mechanism of this loss of complex IV activity. We also confirmed that the 78-kDa band is indeed OGT by assaying complex IV immunoprecipitated samples for OGT enzymatic activity. Higher OGT transferase activity was observed within IPs of complex IV from normal samples (Fig. 2E ).
OGA Levels Are Reduced in Diabetic Heart and OGA Activity Occurs Within the Mitochondria. Using an antibody against OGA, thin sections containing purified mitochondria were analyzed by TEM for OGA levels with secondary immune-gold labeling. The data (Fig. 3A) suggest the presence of mitochondria-specific OGA. The levels of OGA decrease in diabetic rat heart mitochondria. These findings partially explain why O-GlcNAc levels in mitochondria are up-regulated in diabetic samples. To further visualize the presence of mitochondrial OGA, we immunostained for OGA and mitochondria (using mito-tracker RED). Immunofluoresence imaging of labeled cells show significant colocalization between OGA antibody and mito-tracker (Fig. S2) . Because hydrolase activity from purified mitochondria is inherently problematic due to the low levels of lysosomal impurities (24), we used live cell imaging analysis to ascertain mito-specific OGA activity. Neonatal rat cardiomyocytes were plated and allowed to grow in 5 mM glucose media (25) , which were then treated with two inhibitors, Thiamet G (TMG), which is highly specific for OGA (26) , and M-31850 for lysosomal hexosaminidases (IC 50 for Hex A and Hex B are 6 and 3.1 μM, respectively). Two hours after treatment, the cells were fed the OGA substrate, fluoresceinGlcNAc. The cells were also treated with Tetramethyl Rhodamine Methyl ester (TMRM) and Hoesht for mito-tracking and nuclear localization. Live cell imaging showed significantly enhanced fluorescence signal from hydrolyzed fluorescein-GlcNAc within cells treated with M-31850 compared with TMG-treated cardiomyocytes ( Fig. 3 C and D, green filter), indicating that the observed activity differences were OGA specific. For mitochondria-specific activity, TMRM signals were used to segment areas within cells and the fluorescein intensity within these areas were measured. Total segmented fluorescein intensity is also significantly higher within M-31850-treated cells (Fig. 3D ), indicating that cardiomyocyte mitochondria retain substantial OGA hydrolysis activity. This is the first demonstration to our knowledge that OGA is indeed present within the mitochondria.
Radioactive 3 H UDP-GlcNAc Is Efficiently Transported into Purified Rat
Heart Mitochondria. The transport of nucleotide sugars into the mitochondrial matrix has not been investigated. To ascertain whether UDP-GlcNAc could be transported through the mitochondrial membranes, we used radioactive UDP-GlcNAc to query whether purified mitochondria from rat hearts would efficiently incorporate the nucleotide sugar. As shown in Fig. 4A , we observed effective uptake of the nucleotide sugar by purified rat heart mitochondria. The transport was affected by uridine nucleotides, UTP and UMP, but remained unaffected by ATP, membrane decouplers [Carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone, FCCP] and mitochondrial permeability transition pore inhibitors. Control mitochondria treated with 1% triton lost a significant amount of the transported UDP-GlcNAc. We analyzed the ability of the inner mitochondrial membrane to control transport function. Mitoplast preparations ( Fig. 4B ) used in the transport assay (Fig. 4C) show that mitoplasts are also capable of transporting UDP-GlcNAc, which is affected by pore-forming toxins (27) , hinting that inner membrane transporter proteins may be responsible for UDPGlcNAc transport. We confirmed this hypothesis by using known mitochondrial inner membrane transporter inhibitors in our radioactive uptake assay. The data showed that only two inhibitors produced a significant loss in transport of radioactive UDPGlcNAc. Pyridoxal phosphate, a universal mitochondrial transporter inhibitor and bathophenanthroline, reportedly affecting one of the pyrimidine nucleotide carriers (pnc1) or deoxy nucleotide carrier (dnc) (28, 29) . Our data suggest that either of these two transporters might be responsible for uptake of UDP-GlcNAc into the mitochondrial matrix (Fig. 4D ).
Pnc1 Transporter Protein (SLC25A33) Is Responsible for Transport of
Mitochondrial UDP-GlcNAc. We reconstituted transport activity in vitro using liposome-protein preparations. Toward this aim, we obtained the expression plasmid for the dnc (29) and pnc (30) genes. Proteins were expressed in Escherichia coli, and overexpressed proteins were purified (31) and used for preparation of proteoliposomes for analysis of transport activity. Phosphatidylcholine (PC) liposomes mixed with protein and 10 mM nucleotide sugar in buffer were detergent exchanged to generate proteoliposomes. Dynamic light scattering spectroscopy was used to determine the size and polydispersity (Fig. S3A ) of the liposomes. Subsequently, the liposomes were used to determine transport of radioactive UDP-GlcNAc. Control experiments were set up using liposomes that were preincubated with 20 mM bathophenanthroline and liposomes containing the Sodium Bicarbonate Cotransporter (NBC). Transport data suggested that the pyrimidine nucleotide carrier, pnc1, may be a major transport protein responsible for uptake of UDP-GlcNAc ( Fig. 5A ), although the deoxy nucleotide carrier also showed significant uptake. We also analyzed a number of nucleotide substrates that may act as exchange substrates for UDP-GlcNAc and found UDP to give the highest transport activity (Fig. 5B ), indicating that pnc1 may act as an antiporter. Using a stealth siRNA, we were successful in knocking down pnc1 protein partially from HeLa cells ( 
TMG and Ac 4 SGlcNAc Affect ATP Levels and Mitochondrial Membrane
Potential in Neonatal Rat Cardiomyocyte Cells. Our data show that rat heart mitochondria contain both OGT and OGA, whose levels and localization are altered in diabetes. To interrogate effects of inhibiting these key enzymes on cardiac tissue, we used neonatal rat cardiomyocyte (NRCM) culture to access the functional effects of altering O-GlcNAcylation on NRCM. For this analysis we used a short-term treatment of TMG and peracetyl thio-GlcNAc (Ac 4 SGlcNAc) as inhibitors for OGA and OGT, respectively (6 h for TMG and 18 h for Ac 4 SGlcNAc). Western blotting of whole cell lysates and mitochondrial fraction of cardiomyocytes confirm effective inhibition of both these enzymes (Fig. 6A) . Inhibitor-treated cells were also used to determine total cellular ATP levels. OGA inhibition using TMG lowers the total cellular ATP levels by 40% compared with normal glucose, whereas inhibition of OGT did not significantly alter the overall ATP levels (Fig. 6B) . Reduced mitochondrial membrane potential attenuates total ATP generated by the mitochondria and can cause dysfunction in cardiac mitochondria. To investigate how O-GlcNAc affects membrane potential, we tested mitochondrial potential in NRCMs after inhibition of OGT and OGA. Using live NRCMs, relative membrane potentials were determined by using a membrane potential activated dye, JC-1. We also used a mitotracker RED dye to look at fixed cells that were pretreated with the inhibitors. Both live and fixed cell analysis showed that cells treated with TMG had significantly reduced membrane potential compared with control cells (Fig. 6  C and D) , whereas upon Ac 4 SGlcNAc treatment, a slight strengthening of the potential was observed (Fig. 6 C and D) . Inhibition of neonatal rat cardiomyocyte OGT and OGA using Ac 4 SGlcNAc and TMG, respectively, showed that short-term treatment of these enzymes significantly affect total cellular ATP levels and mitochondrial membrane potential. We decided to query whether OGT and OGA inhibition had an effect on mitochondrial oxygen consumption. For these measurements, we used XF96 seahorse analysis. Cardiomyocytes plated in 96-well plates were treated with Ac 4 SGlcNAc and TMG as described. The cells were then put in the seahorse analyzer and basal oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) were obtained, after which the cells were subsequently treated with oligomycin, FCCP, rotenone and antimycin, and both OCR and ECAR were measured. Our data ( Fig. 6E and Fig. S4 ) suggest that short-term TMG treatment significantly increases basal oxygen consumption. A significant portion of this increase seems to be ATP linked, which points to the loss in total cellular ATP levels as observed in Fig. 6C and the corresponding lowering of membrane potential. Conversely, OGT inhibition slightly lowers basal mitochondrial oxygen consumption. Maximal OCR levels remain unchanged between untreated and TMG-treated cells, whereas inhibition of OGT seems to slightly lower maximal OCR levels. This may be due to the slight increase in mitochondrial membrane potential as observed in Fig. 6 C and D. Also, probably as a result of increased basal OCR, mitochondrial reserve capacity is lowered significantly upon TMG treatment. A look at the cellular glycolytic rate (Fig. 6F ) reveals that both TMG and Ac 4 SGlcNAc increases the glycolytic rate, although the increase due to TMG is much higher. TMG also elevates the maximal glycolytic capacity, which OGT inhibition does not seem to affect. In this regard, lowering of the basal OCR levels and maximal OCR levels upon Ac 4 SGlcNAc treatment might indicate a mito-specific effect of OGT inhibition in the neonatal rat cardiomyocytes, underscoring the important role of mitochondrial OGT in its function.
Discussion A significant volume of literature suggests that O-GlcNAcylation is a nutrient and stress sensor. Mitochondria-the cells' own energy generator-is significantly affected by alterations in nutrient types and levels. Recent research in the field has attempted to understand how mitochondrial function is affected by alterations in cellular O-GlcNAc without focusing on the raw materials that alter O-GlcNAc cycling within the mitochondria. This paper attempts to understand how the enzymes responsible for O-GlcNAc cycling affect mitochondrial O-GlcNAc and its functioning. The observation that OGT levels are increased in diabetic mitochondria, without significantly affecting its in vitro specific activity, hints at the aberrant nature of OGT functioning within diabetic organelles. Interestingly, EM data suggest a loss of membrane association for OGT in diabetic mito samples; this alteration in localization likely changes the subset of proteins that get O-GlcNAc modified within diabetic tissues, thereby implicating altered O-GlcNAc status of mitoproteins in certain mitochondrial dysfunction observed during diabetes. This loss of membrane-associated protein-OGT interaction is observed in complex IV-OGT interaction that falls off in diabetic samples. The OGT isoform observed in this case seems to be the short 78-kDa form, although there is a possibility that this observed band is just a proteolytic fragment of the mitochondrial OGT. Complex IV activity is significantly reduced in diabetic mitochondria and its OGT association may be a reason for its loss of functionality.
In our study, we observe OGA levels in normal mito by EM, which is reduced in diabetic samples. We also show by Immuno Fluoresence (IF) analysis that OGA colocalizes with mito-tracker RED in both NRCMs and NIH 3T3 cells. Our live cell assay shows that a significant portion of the cellular OGA activity occurs within the mitochondria. Taken together with the presence, localization, and interaction of mito-specific OGT, this observation for the first time to our knowledge puts both of the two cycling enzymes within the mitochondria, thus indicating real-time O-GlcNAc cycling occurs inside the mitochondrion.
We also show here that purified mitochondria are indeed capable of transporting UDP-GlcNAc, and this transport is affected specifically by UTP nucleotides. Using mitoplast preparations, inhibitorbased transport assays and in vitro liposome assay, we identified the pyrimidine nucleotide carrier as a mitochondrial transporter responsible for transport of UDP-donor sugar. Finally using stealth siRNA-based knockdown assay, we observed significant loss of O-GlcNAc levels in mitochondrial O-GlcNAc and a lowering of UDP-GlcNAc transport capacity. This finding implicates pnc as the significant contributor to mitochondrial UDP-GlcNAc levels. It must be acknowledged that even though pnc seems to be the predominant transporter for UDP-GlcNAc, the deoxyribonucleotide carrier (dnc) also transported a certain amount of the external radioactivity. Given the structural similarities of these transporters as well as the substrates they reportedly transport, both of these proteins could be partially responsible for uptake of nucleotide sugars.
Finally, our results indicate a real effect of OGT/OGA inhibition on mitochondrial function. Short-term inhibition of OGA lowers ATP levels and mitochondrial membrane potential. Concurrently at the basal level, we observe a significant increase in mitochondrial oxygen consumption upon TMG treatment. There is also an increase in basal glycolytic rate upon TMG treatment. These observations can be understood as an increase in overall cellular metabolic rate, which effects glycolysis, oxygen consumption, and membrane potential. These data indicate shortterm increase in O-GlcNAc levels allows the cell to become more metabolically active and possibly assists in cardioprotection. Conversely, targeting OGT slightly strengthens mitochondrial membrane potential and cellular ATP levels. The ECAR data show a slight increase in glycolytic rates upon OGT inhibition, whereas a decrease in OCR is observed. This finding indicates that OGT's effects may be more mitoprotein specific and that lowering of O-GlcNAc possibly lowers mitochondrial metabolism rates.
In conclusion, through this work we characterize the players in O-GlcNAc cycling within the mitochondria. We delineate how the enzyme levels, their location, and their interactions change in going from normal to diabetic heart samples. We show for the first time to our knowledge mito-specific OGA activity within live neonatal rat cardiomyocytes. And we report the presence of a mitochondrial transporter that uptakes UDP-GlcNAc. A knockout of one of these transporters also lowers the O-GlcNAc levels in the mitochondria. Because O-GlcNAcylation is highly dynamic, the presence of the full repertoire of responsible elements in the mitochondria indicates effective machinery that possibly alters the mitochondria's functioning in response to not just nutrient and other cellular stresses but also to alteration in overall cellular O-GlcNAcylation conditions. Overall, current data suggest that O-GlcNAcylation not only plays a role in nutrient regulation of mitochondrial functions, but also its alterations in diabetes, both in terms of extent and types of proteins modified, plays a role in mitochondrial dysfunction in diabetic heart tissue.
Materials and Methods
Animals and Mitochondrial Purification. All rats were treated in accordance with animal safety regulations according to The Johns Hopkins University School of Medicine. Rat hearts were taken from both diabetic and control animals and used for mitochondrial purification. See SI Materials and Methods for further details.
NRCM Mitochondrial Oxygen Consumption. Live cell oxygen consumption was measured by using a XF96 flux analyzer. The oxygen consumption rate was measured over a period of 100 min over which time oligomycin, FCCP, antimycin A, and rotenone and iodoacetate were sequentially added to each well. See SI Materials and Methods for further details.
Live Cell OGA Activity Assay. Cardiomyocytes were treated with OGA and lysosomal hexosaminidase inhibitors and used to determine live cell mitospecific OGA activity. See SI Materials and Methods for further details.
Generation of Proteoliposomes for UDP-GlcNAc Uptake Assay. Liposomes were generated and transport of radioactive UDP-[ 3 H]GlcNAc was carried out as described (31, 32) . See SI Materials and Methods for details.
Statistics. Data from Western blots and IF samples were processed by ImageJ quantification software. All data are expressed as mean ± SD. Each 'n" represents the number of rats used or the number of biological repeats as applicable. Comparisons between different groups were performed with the use of a two-tailed, unpaired Student t test, with P < 0.05 considered significant.
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SI Materials and Methods
Reagents and Cell Culture. All chemical reagents were obtained from commercial sources and used without purification unless otherwise noted. Dulbecco's Modified Eagle Medium (DMEM), penicillin-streptomycin, and 0.5% (vol/vol) Trypsin-EDTA was purchased from Gibco. FBS was purchased from HyClone. Primary Neonatal Rat Cardiomyocytes (NRCM) was prepared as per established protocol (1). NRCMs were plated onto 0.1% (wt/vol) gelatin-coated dishes and grown on DMEM containing 25 mM glucose media containing 5% (wt/vol) FBS and 1% pen-strep for 24 h, after which time the medium was changed to DMEM with 5 mM glucose containing 1% (wt/vol) FBS and 1% (wt/vol) penstrep and the mediim was changed every 24 h. Antigen purified CTD 110.6 (2) was used for O-GlcNAc-specific immunoblots. Protein-specific antibodies were obtained from the following: complex II (Abcam; MS203), complex IV (Abcam; MS407), OGT (antigen-purified AL03) (3), OGA (antigen-purified 345) (4), tubulin (Sigma; T3526), iron sulfur subunit of succinate dehydrogenase (Abcam; 21A11AE7), and voltage-dependent anion channel (Sigma; V2139). A total of 50 nm gold-labeled anti-rabbit, anti-mouse, and anti-chicken antibodies were obtained from The Jackson Laboratories. Thiamet G was obtained via custom synthesis from SD Chem Molecules. Ac 4 SGlcNAc was synthesized in laboratory via already published protocol (5).
Animals. All rats were treated in accordance with animal safety regulations according to The Johns Hopkins University School of Medicine. The 2-to 3-wk-old male (250 g) Sprague Dawley rats were purchased from Harlan Laboratories. Diabetes was induced by i.p. injection of 65 mg of streptozocin (STZ; Sigma-Aldrich) per kilogram of body weight as described previously (6) . Control animals received injections of 100 mM citric acid (pH 4.5). Blood glucose was checked after 7 d and animals were killed after 4-5 wk and with their blood glucose levels over 600 ng/dL. Rat hearts were taken from both diabetic and control animals and used for mitochondrial purification.
Mitochondria Purification. Mitochondria were isolated by differential centrifugation protocol as described previously (7). All following operations were performed at 4°C and under low light conditions. Briefly, about 250 mg of freshly obtained heart tissue were pulverized and then homogenized in 1 mL of modified isolation buffer (IS) (220 mmol/L mannitol, 70 mmol/L sucrose, 5 mmol/L EDTA, 20 mmol/L Hepes, pH 7.4) plus EDTAfree protease inhibitor mixture tablet (Roche). The sample was centrifuged at 800 × g for 5 min at 4°C and the pellet was resuspended in 1 mL of homogenization buffer and centrifuged as above. This step was repeated twice. Supernatants from each step were pooled and centrifuged at 8,000 × g for 10 min at 4°C. The resulting pellet was resuspended in 1 mL of the isolation buffer and centrifuged at 8,000 × g for 15 min. The pellet was then resuspended in 1 mL IS. These pellets resuspended in IS buffer were further purified on a 17-35% histongenz gradient in an ultracentrifuge. The mitochondrial pellet at the junction between 35% and 17% histongenz was collected and used for Western blotting, activity assays, nucleotide sugar uptake, and electron microscopy. Mitochondria were stored at −80°C as 100-μg aliquots until use. For the isolation of mitochondria from NRCM cells, cells from 100-mm plates were washed twice with cold PBS and scraped into 2 mL of cold PBS supplemented with protease inhibitor mixture. The samples were centrifuged at 470 × g for 5 min at 4°C and the pellets were homogenized in 1 mL of homogenization buffer (220 mmol/L mannitol, 70 mmol/L sucrose, 20 mmol/L Hepes, pH 7.4) with protease inhibitor mixture. The sample was centrifuged at 600 × g for 5 min at 4°C and the pellet was resuspended in 100 μL of homogenization buffer and centrifuged as above. Supernatants from each step were pooled and centrifuged at 10,000 × g for 5 min. The final pellet was resuspended in 50 μL of homogenization buffer and protein concentration was determined by CB-X protein assay kit (G-Biosciences). Mitochondria were stored at −80°C as 20-μg aliquots until use.
Electron Microscopy and Confocal Microscopy. Samples were fixed in 4% paraformaldehyde + 0.2% glutaraldeyde + 0.1 M phosphate buffer (Sorenson's) + 3 mM MgCl2 pH 7.2-7.4 overnight at 4°C. Fixation and all subsequent steps up to infiltration were carried out at 4°C, followed by curing at 50°C. After a 45-min buffer rinse (0.1 M phosphate + 3% sucrose), samples were incubated with 0.12% tannic acid (Malinkrodt) in buffer for 1 h. Uncrosslinked glutaraldeyde was reduced for 30 min with 50 mM NH4Cl in buffer. Tissue was then en-bloc stained in 2% uranyl acetate (filtered) in maleate for 30 min. After a graded ethanol series dehydration, samples were infiltrated with a 2:1 90% ethanol:LR White resin (with catalyst), followed by 1:1, then 1:3 mixture for 40 min each. Samples were further infiltrated in pure LR White overnight at 4°C. Finally, samples were polymerized in tightly sealed gelatin capsules at 50°C, for 24 h. Polymerized blocks were trimmed and sectioned on a Reichert Ultracut E Microtome, using a low angle Diatome diamond knife. The 70-to 80-nm thin sections were collected on formvar-coated 200 mesh nickel grids (Pella) and processed for immunolabeling. Grids were floated, section side down in 50 mM NH4Cl in TBS for 10 min. Upon a 10-min block in 1% BSA/TBST, grids were incubated with primary antibodies (1:100-OGT, 1:100-OGA and CTD 110) in 1% BSA/TBST overnight at 4°C. No primary antibody served as negative controls. Grids were allowed to come to room temperature for 1 h after primary antibody incubation, then incubated for 10 min on 1% BSA/TBST. After rinsing in TBS, grids were sequentially incubated in secondary Aby gold conjugate (6 nm Au-Goat anti-mouse, 1:40 dilution or 6 nm AuGoat anti-rabbit in TBS; The Jackson Laboratories) for 1.5 h at room temperature. After rinsing in TBS then D-H 2 O, grids were incubated in 2% glutaraldehyde (aqueous) for 5 min, then rinsed again in D-H 2 O. After rinsing, grids were stained with 2% filtered Uranyl Acetate (aqueous) for 10 min and then allowed to dry. All grids were viewed with a Hitachi H-7600 TEM operating at 80 kV and images were captured with an XR 50-5 Megapixel CCD camera by AMT.
For immunofluorescence, NRCMs were plated on gelatincoated coverslips, allowed to grow for at least 5 d in DMEM containing 5 mM glucose, and were treated with mito-tracker red dye (M7512; Life Technologies) for 30 min. The cells were then fixed with 4% paraformaldehyde and permeabilized with 0.5% Triton X-100 in PBS. Following this step, the cells were blocked with 5% BSA and treated with antibodies for OGT (AL-03) and OGA (345) and subsequently with secondary antibodies (anti-IgG 488-conjugated Alexa Fluor; Invitrogen). The coverslips were then briefly stained for DNA with Dapi and mounted on a slide. Images were captured on a laser scanning Zeiss 510-Meta confocal microscope and acquired as a z stack of five 1-μm slices spanning a 2.8-μm range.
NRCM Mitochondrial Oxygen Consumption. Live cell oxygen consumption was measured by using a XF96 flux analyzer (Seahorse Biosciences). NRCM mitochondrial oxygen consumption assays were carried out in a seahorse 96-well cell culture plate with a XF96 sensor cartridge. The XF96-well plates were treated with 0.1% gelatin before the primary cardiomyocytes were plated at a density of 10,000 cells per well. Cells were allowed to grow for 5 d before treating them with Ac 4 SGlcNAc and TMG, 24 h before oxygen consumption assays. Cells were incubated with unbuffered DMEM with 5 mM glucose and containing 200 mM glutamine, NaCl in a C0 2 -free incubator at 37°C for 1 h before loading the plate in the XF96 analyzer. The oxygen consumption rate was measured over a period of 100 min over which time oligomycin (0.5 μM), FCCP (0.3 μM), and both antimycin A (0.2 μM) and rotenone (0.1 μM) were sequentially added to each well at specified time points. The extracellular acidification rate (ECAR) was also measured over the same treatment and time.
Whole Cell ATP and Mitochondrial Membrane Potential Measurements.
NRCMs treated with inhibitors of OGT and OGA were collected and pelleted. The cell pellets were ruptured using a homogenizer and mitochondria were prepared using differential centrifugation. The mitochondrial pellets were lysed and ATP levels determined using a luminescence assay as specified (ATP determination kit; Molecular Probes). For membrane potential determination, inhibitor-treated cells were incubated with mito-tracker dyes (M7512; Life Technologies) and JC-1 for 30 min. Cells treated with mito-tracker red (M7512; Life Technologies) were fixed with 4% paraformaldehyde and mounted on slides for immunofluorescence. Live cells treated with JC-1 (Life Technologies) were imaged directly on a laser scanning Zeiss 510-META confocal microscope. Relative membrane potential was assessed by the ratio of red to green fluorescence.
Complex IV, OGT, and OGA Activity Assays. For enzyme activity assays purified mitochondria from normal and STZ-treated rats were lysed using a 1% Triton lysis buffer. The mitochondrial lysate was desalted on a G50 desalting column and used for radioactive OGT activity assay (8) . The lysate proteins were precipitated using an ammonium sulfate solution and the precipitated proteins resuspended in a 20 mM Hepes buffer containing 60 mM NaCl and used for OGA activity assay using 4MU as a substrate (9, 10) . For mitochondrial complex IV activity assays, the lysates were added on to a 96-well plate complex IV activity assay kit (ab109911; Abcam,). After 3 h of incubation, the wells were washed with buffer and a solution of 50 mM reduced cytochrome c was added to the wells. Oxidation of cytochrome c was followed continuously for 30 min by measuring absorbance at 550 nm. The loss in absorbance was plotted against time and the initial slope was used to calculate activity of complex IV in the different mitochondrial samples.
Live Cell OGA Activity Assay. Cardiomyocytes were plated on glassbottom dishes at concentrations of 5 × 10 4 cells per milliliter. Cells were allowed to grow in 5 mM glucose media for 5 d. Subsequently the cells were treated with either 2 mM TMG (10) (OGA inhibitor) or 2 mM M-31850 (lysosomal hexosaminidase inhibitor, EMD Biosciences). After 2 h of treatment GlcNAcfluorescein was added to the cells at a final concentration of 2 μM. After 90 min of substrate addition, mito-tracker dye TMRM (Molecular Probes) was added to the cell at the recommended concentration. Finally within 30 min of TMRM addition, Hoesht was added to the media, just before imaging the cells. Imaging was carried out in a laser scanning Zeiss 710 NLO 2 photon confocal microscope and acquired as a z stack of seven 1-μm slices spanning a 2.8-μm range. Colocalization between the green channel (for hydrolyzed GlcNAc-fluorescein) and red channel (TMRM) was used to determine mito-specific activity of OGA.
Immunoprecipitation and Immunoblotting. Endogenous complex IV was immunoprecipitated by incubating 2 μg of antibody specific for Complex IV (Abcam; MS402) with 2 mg of purified rat heart mitochondrial lysate (2 mg/mL) overnight at 4°C on a rotator. Samples were subsequently incubated with 5 μL GammaBind G-Sepharose beads (GE Healthcare) for 2 h at 4°C on a rotator and subjected to five 5-min washes with 500 mM NaCl lysis buffer. For all experiments, washed immunoprecipitates were eluted with Laemli buffer.
For immunoblots, 20-60 μg of Laemli solubilized lysate or eluted immunoprecipitates were boiled, separated on Criterion precast SDS-polyacrylamide gels (Bio-Rad), and transferred to nitrocellulose (Millipore). Membranes were blocked for 1 h in Tris-buffered saline supplemented with 0.1% (vol/vol) Tween-20 (TBST) and 5% (wt/vol) nonfat dry milk or BSA and incubated with respective primary antibodies overnight at 4°C. Membranes were washed, incubated with the appropriate HRP-linked secondary antibody for 1 h, washed again, developed using HyGLO quick spray (Denville Scientific) [or SuperSignal West Femto (Thermo Scientific) when appropriate] ECL detection reagent, and exposed to Hyperfilm ECL (GE Healthcare).
Clear and BN PAGE Analysis. Blue Native PAGE (BN-PAGE) was used to resolve the native, intact mitochondrial protein complexes (11) . Briefly, mitochondria samples were solubilized in BN-PAGE sample buffer [50 mmol/L Tris·HCl, 50 mmol/L NaCl, 10% glycerol (wt/vol), 0.001% Ponceau S, pH 7.2 plus protease inhibitor mixture] with 2% digitonin (wt/vol) at about 5 μg/μL and incubated on ice for 30 min. Each sample was centrifuged for 30 min at 22,000 × g at 4°C. The supernatant was collected and 50 μg of protein was mixed with 5% (wt/vol) Coomassie G250 to a final concentration of 0.4%, then loaded on a 3-12% NativePAGE Novex gel (1 mm, Invitrogen) and run according to the manufacturer's protocols. The gel was either transferred to PVDF membrane (Millipore; 45 μm) for Western blotting or separated by a second dimension SDS/PAGE. Upon completion of 1D BN-PAGE whole lanes were excised from the gel into 15-mL tubes for incubation in 1× NuPAGE LDS sample buffer [Invitrogen; 62 mmol/L Tris, 0.5% (wt/vol) LDS, 2.5% glycerol, 0.13 mmol/L EDTA, 0.55 mmol/L Coomassie G250 and 0.04 mmol/L phenol red, pH 8.5] with or without 50 mmol/L DTT, for reducing and nonreducing PAGE, respectively, at 37°C for 30 min on a Nutator. Gel slices were placed on the top of an 18-cm 10% SDS/PAGE gel (1.5 mm, homemade) and overlaid with 0.5% agarose. The gels were run using Mes running buffer [50 mmol/L Mes, 50 mmol/L Tris-base, 0.1% (wt/vol) SDS, 1.0 mmol/L EDTA, pH 7.3] at 70 V (2 h) and 90 V (16 h). Gels were either fixed in 50% (vol/vol) methanol, 10% (vol/vol) acetic acid, or transferred to nitrocellulose membrane for Western blotting as described above. To ascertain the possible influx of UDP-GlcNAc, substrate for protein O-GlcNAcylation, into the mitochondrial matrix, purified mitochondria from rat heart tissue was incubated with 3 H UDP-GlcNAc. Mitochondria from normal rat hearts was purified as described above and resuspended in a buffer used to study mitochondrial respiration (20 mM Hepes, 250 mM sucrose, and 10 mM MgCl 2 , pH 7.02). The mitochondria were incubated with 1 μCi of 3 H UDP-GlcNAc for 5, 10, 15, or 30 min. Uptake was also analyzed in the presence of 500 μM of ATP, UTP, UDP, UMP, etc. Mitochondria incubated with radioactivity and containing 1% detergent was used as negative controls. Following incubation the mitochondria were pelleted by centrifugation at 10,000 × g. The pellet was then resuspended in buffer free of radioactivity and the mitochondria were again pelleted at 10,000 × g. This step was repeated three times. The remaining radioactivity within the mitochondrial pellet was then measured in a scintillation counter. Concentration of transported UDP-GlcNAc per milligram of mitochondrial protein was plotted. Further analysis of nucleotide sugar uptake was carried out using purified mitoplasts in the same way as described above. Mitoplasts were prepared as described elsewhere (12) . Control mitoplasts were also incubated with a solution of 10 mM streptolysin O.
For inhibition analysis of putative mitochondrial carriers, purified mitochondria was preincubated for 15 min with 20 mM butyl malonate, 50 mM bathophenanthroline, 20 mM pyridoxyl phosphate, 15 mM ethylmalemide, 20 mM phenyl succinate, and 20 mM cyanohydroxycinnamate followed by regular uptake assay as described above.
Cloning, Expression, and Purification of Pyrimidine Nucleotide Carrier and Deoxyribonucleotide Carrier. Plasmids expressing the dnc and pnc gene were obtained from Sarah O'Conner, National University of Ireland, Cork and Fernando Palmieri, University of Bari, Italy, respectively (13, 14) . The proteins were expressed in bacteria using appropriate antibiotic selection and IPTG induction. The cell pellet was resuspended in 20 mM Tris containing 50 mM DTT and passed through a French press to lyse cells. The supernatant was removed and the pellet was again resuspended in 20 mM Tris, 1 mM DTT pH 7.02 buffer, and loaded on to a 30-70% sucrose density gradient to separate the inclusion bodies.
Generation of Proteoliposomes Containing Intermembrane PNC and DNC Proteins and Analysis of UDP-GlcNAc Uptake by These Liposomes.
To 100 mg of powdered phospatidylcholine (PC) was added 1 mL of sterile water and the mixture was incubated for 3 h with periodic vortexing and bath sonication. Meanwhile the extruder was set up by putting a 0.1-μm filter between the two syringe units and residual air was removed by pushing water through the filter. The PC-water mix was extruded through the 0.1-μm filters 11 times such that the last extrusion completes in the syringe opposite to the one initially filled. Liposome prep was removed and stored in an Eppendorf tube at 4°C for 5 d. A working mixture of liposome, protein, and detergent was prepared by taking 10 μg of purified protein (in inclusion bodies) and adding 60 μL of Triton X-114. To the mix 200 μL of PC liposome was added. The total solution was made up to 700 μL by adding a 20 mM Hepes buffer containing 20 mM NaCl and 10 mM nucleotide (UTP, UDP, etc.). This was vortexed a couple of times and passed through a XAD2 amberlite ion exchange resin for 13-20 consecutive times to exchange detergent and incorporate protein into liposome membrane (15) . Subsequently, excess nucleotide was separated from liposome by passing the mixture through a G50 column. The resultant proteoliposome was used for DLS analysis. For uptake assay, 200 μL of the prepared proteoliposome was incubated with 1 μCi of 3 H UDP-GlcNAc for 20 min, at the end of which, 20 mM bathophenanthroline was added to stop uptake. The mixture was purified on a G50 column to remove excess radioactivity and the resultant . Immunofluoresence imaging of neonatal rat cardiomyocytes and NIH 3T3 cells stained for nucleus (DAPI), OGA (anti-OGA antibody, 345), and mitochondria (mito-tracker red). Cells were treated with mito-tracker then fixed and permeablized after which they were stained for OGA. Images were taken in a confocal microscope. Colocalization analysis was done on z-stack images using Imaris software.
